期刊文献+

冠心病二级预防用药出院带药情况分析 被引量:5

Analysis on Prescribed Medications for Discharged Patients in Secondary Prevention of Coronary Heart Disease
下载PDF
导出
摘要 目的:通过调查冠心病(CHD)患者出院带药情况,了解CHD二级预防药物的使用情况。方法:对张掖市人民医院近3年296例CHD患者出院带药情况(主要为二级预防药物)进行回顾性分析。结果:296例CHD患者中266例有出院带药记录。出院带药情况为:抗血小板药(97.7%)、他汀类药物(87.7%)、β受体阻断剂(71.4%)、血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体拮抗剂(ARB)(64.3%),平均带药种类为(3.25±0.8)种。结论:从CHD二级预防药物出院带药率情况来看,该院医生对CHD二级预防非常重视,但存在指导用药不规范的问题,抗血小板药、他汀类药物带药率高,β受体阻断剂、ACEI/ARB带药率较低。 Objective: To know the conditions of secondary prevention medicine through surveying the prescribed medications for discharged patients with coronary heart disease (CHD). Method: The prescribed medications (mainly secondary prevention medicine) for 296 patients discharged from people's hospital of Zhangye in recent three years were retrospectively analyzed. Result: There were 266 patients with the records of prescribed medications when discharged among 296 patients. The conditions were: antiplatclet drugs (97.7%), statins (87.7%), receptor blocker(71.4%), ACEI/ARB(64.3%), average types of drugs (3.25±0.80). Conclusion: Doctors emphasize secondary prevention of CHD from the conditions of prescribed medications when CHD patients were discharged, but the prescribed medications are confused and need to be improved, antiplatelet drugs and statins are prescribed more when CHD patients were discharged, while β receptor blocker and ACEI/ARB are prescribed less.
作者 马丽
出处 《西部中医药》 2013年第7期58-60,共3页 Western Journal of Traditional Chinese Medicine
关键词 冠心病 二级预防 出院带药 调查分析 coronary heart disease (CHD) secondary prevention prescribed medications when discharged investigation
  • 相关文献

参考文献8

二级参考文献159

共引文献6000

同被引文献67

  • 1陈洁清,黎观梅,杨齐.社区护理对冠心病合并高脂血症患者遵医行为的影响[J].护理学报,2006,13(10):57-58. 被引量:21
  • 2赵冬,刘群.中国冠心病二级预防架桥工程进展——初步调查结果分析报告[J].中华医学信息导报,2007,22(1):19-19. 被引量:18
  • 3Young YX,Jabbour S,Golderg R. Usefulness of starlin drougs inprotecting against atrial fidrilation in patients with coronary artery disease[J].{H}American Journal of Cardiology,2003.1379-1383.
  • 4Ahem RM, Lozano R, Naghavi M, et al. Improving the public health utility of global cardiovascular mortality data : the rise of isehemic heart disease[J]. Popul Health Metr,2011,9:8. DOI: 10. 1186/ 1478-7954-9-8.
  • 5Mendes A. Coronary heart disease:self-care, communication and quality of life[J]. Br J Connnunity Nurs,2015,20( 1 ) :42. DOI: 10. 12968/bjcn. 2015.20.1.42.
  • 6Prior L, Wilson J, Donnelly M, et al. Translating policy into practice : a case study in the secondary prevention of coronary heart disease[ J ]. Health Expect, 2014, 17 (2) : 291-301. DOI: 10. 1111/j. 1369-7625. 2011. 00754. x.
  • 7Matthias AT, Lokunarangoda NC, Ekanayaka R. Knowledge assessment regarding secondary prevention of coronary heart disease- a multi centre survey[ J]. BMC Medical Education ,2014, 14:113. DOI: 10. 1186/1472-6920-14-113.
  • 8Stone GW, Aronow HD. Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy [ J ]. Mayo Clinic Proceedings, 2006,81 ( 5 ) : 641-652. DOI : 10. 4065/81 5. 641.
  • 9Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study ):a prospective epidemiological survey [ J ]. Lancet,2011,378 ( 9798 ) : 1231-1243. DOI:10. 1016/S0140-6736 (11)61215-4.
  • 10王强.冠脉支架术后患者支架内再狭窄原因的回顾性研究[D].苏州:苏州大学,2012.

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部